Stryker (NYSE:SYK) Stock Price Target Cut by Barclays

Key Points

• Barclays cut Stryker’s price target to $365 from $375 while maintaining an “overweight” rating, implying approximately 23.8% upside from the reported share price.
• Stryker shares fell 5.4% to $294.81 after the company reported quarterly EPS of $3.52 and revenue of $6.52 billion, both below analyst expectations, despite 7.6% year-over-year revenue growth.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $360.08, but Stryker lowered its 2026 sales-growth and adjusted EPS guidance amid weaker demand, supply disruptions and cybersecurity-related operational challenges.

Stryker (NYSE:SYK - Get Free Report) had its price objective reduced by Barclays from $375.00 to $365.00 in a report issued on Friday, Benzinga reports. The firm presently has an "overweight" rating on the medical technology company's stock. Barclays's price objective points to a potential upside of 23.81% from the company's current price.

SYK has been the subject of several other reports. Wells Fargo & Company decreased their price objective on Stryker from $418.00 to $348.00 and set an "overweight" rating for the company in a research report on Wednesday, September 9th. Royal Bank Of Canada cut their price target on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. UBS Group started coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a "buy" rating and a $400.00 price target for the company. Weiss Ratings reissued a "hold (c)" rating on shares of Stryker in a research report on Thursday. Finally, Citizens Jmp dropped their price objective on shares of Stryker from $400.00 to $390.00 and set a "market outperform" rating on the stock in a report on Friday. Seventeen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $360.08.

Stryker Trading Down 5.4%

Stryker stock traded down $16.94 during mid-day trading on Friday, hitting $294.81. The stock had a trading volume of 2,812,019 shares, compared to its average volume of 2,455,312. The stock has a 50-day simple moving average of $293.56 and a two-hundred day simple moving average of $324.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $113.08 billion, a PE ratio of 30.50, a P/E/G ratio of 1.96 and a beta of 0.78. Stryker has a 12 month low of $267.00 and a 12 month high of $389.33.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm's revenue for the quarter was up 7.6% on a year-over-year basis. During the same period last year, the firm earned $3.19 earnings per share. As a group, sell-side analysts forecast that Stryker will post 14.93 EPS for the current year.

Insider Buying and Selling at Stryker

In related news, insider Debra King sold 826 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the firm's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Stryker

Several institutional investors and hedge funds have recently made changes to their positions in the business. Gables Capital Management Inc. purchased a new position in shares of Stryker in the 2nd quarter worth about $25,000. Kilter Group LLC bought a new stake in Stryker during the 2nd quarter valued at $25,000. Highland Investment Advisors LLC purchased a new stake in shares of Stryker during the second quarter worth about $25,000. Cornerstone Financial Management LLC raised its position in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Finally, Compass Financial Management LLC bought a new stake in shares of Stryker in the 2nd quarter worth approximately $27,000. Institutional investors own 77.09% of the company's stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter revenue increased approximately 7.6% to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also highlighted strength in the MedSurg business, margin improvement and continued investment in surgical robotics. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Several analysts remain constructive, but lowered their expectations: BTIG Research reduced its target to $304 while keeping a Buy rating, and Citizens JMP cut its target to $390 while retaining Market Outperform. Canaccord Genuity downgraded the stock to Hold and lowered its target to $300, signaling more limited near-term upside. Stryker analysts cut their forecasts
• Negative Sentiment: Quarterly adjusted EPS of $3.52 missed the roughly $3.55–$3.56 consensus, and revenue of $6.52 billion fell short of the $6.62 billion estimate. The company cited softer joint-replacement demand, manufacturing and vascular supply disruptions, and lingering operational effects from its cybersecurity incident. SYK Q3 earnings call highlights
• Negative Sentiment: Stryker cut its 2026 organic sales-growth forecast to 6.5%–7.0% from 8.3%–9.3% and reduced adjusted EPS guidance to $14.80–$14.90 from $14.95–$15.10. The reset, combined with a new CEO taking over amid the challenges, has increased uncertainty about the company’s 2027 starting point. Stryker lowers outlook after third-quarter profit falls

Stryker Company Profile

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.